<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Capsovision, Inc. Common Stock — News on 6ix</title>
<link>https://6ix.com/company/capsovision-inc-common-stock</link>
<description>Latest news and press releases for Capsovision, Inc. Common Stock on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 26 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/capsovision-inc-common-stock" rel="self" type="application/rss+xml" />
<item>
<title>CapsoVision Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/capsovision-inc-common-stock/news/capsovision-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/capsovision-inc-common-stock/news/capsovision-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>SARATOGA, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging</description>
</item>
<item>
<title>CapsoVision Announces $14 Million Private Placement Financing</title>
<link>https://6ix.com/company/capsovision-inc-common-stock/news/capsovision-announces-dollar14-million-private-placement-financing</link>
<guid isPermaLink="true">https://6ix.com/company/capsovision-inc-common-stock/news/capsovision-announces-dollar14-million-private-placement-financing</guid>
<pubDate>Fri, 20 Mar 2026 04:00:00 GMT</pubDate>
<description>Reports Preliminary, Unaudited Fourth-Quarter and Full Year 2025 Financial Results SARATOGA, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (the</description>
</item>
<item>
<title>CapsoVision to Release Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 26, 2026</title>
<link>https://6ix.com/company/capsovision-inc-common-stock/news/capsovision-to-release-fourth-quarter-and-full-year-2025-financial-results-on-thursday-march-26-2026</link>
<guid isPermaLink="true">https://6ix.com/company/capsovision-inc-common-stock/news/capsovision-to-release-fourth-quarter-and-full-year-2025-financial-results-on-thursday-march-26-2026</guid>
<pubDate>Thu, 12 Mar 2026 20:05:00 GMT</pubDate>
<description>Conference Call Scheduled for Thursday, March 26, 2026, at 4:30 pm ETSARATOGA, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that the company will release fourth quarter and full year 2025 financial results on Thursday, March 26, 2026, after the close of market. CapsoVision will host a corresponding conference call and a live webcast a</description>
</item>
<item>
<title>CapsoVision to Participate in the 38th Annual ROTH Conference</title>
<link>https://6ix.com/company/capsovision-inc-common-stock/news/capsovision-to-participate-in-the-38th-annual-roth-conference-12</link>
<guid isPermaLink="true">https://6ix.com/company/capsovision-inc-common-stock/news/capsovision-to-participate-in-the-38th-annual-roth-conference-12</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>- Company to participate in a fireside chat and 1x1 investor meetings on March 23, 2026 - SARATOGA, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- CapsoVision,</description>
</item>
<item>
<title>CapsoVision Announces 510(k) Submission for the Addition of AI-Assisted Reading Module in CapsoCam Plus®</title>
<link>https://6ix.com/company/capsovision-inc-common-stock/news/capsovision-announces-510-k-submission-210500253</link>
<guid isPermaLink="true">https://6ix.com/company/capsovision-inc-common-stock/news/capsovision-announces-510-k-submission-210500253</guid>
<pubDate>Mon, 29 Dec 2025 21:05:00 GMT</pubDate>
<description>Company Preparing to Commence Commercialization Following U.S. FDA 510(k) ClearanceSARATOGA, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced submission of its 510(k) application to the Food and Drug Administration (FDA) for its proprietary AI-assisted module for CapsoCam Plus®. The addition of this reading tool will improve the detection</description>
</item>
<item>
<title>CapsoVision to Participate in the Benchmark 14th Annual Discovery Investor Conference</title>
<link>https://6ix.com/company/capsovision-inc-common-stock/news/capsovision-participate-benchmark-14th-annual-210500219</link>
<guid isPermaLink="true">https://6ix.com/company/capsovision-inc-common-stock/news/capsovision-participate-benchmark-14th-annual-210500219</guid>
<pubDate>Thu, 20 Nov 2025 21:05:00 GMT</pubDate>
<description>Company to participate in 1:1 Investor Meetings on December 4, 2025SARATOGA, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that Johnny Wang, President and Chief Executive Officer, David Garcia, Senior Vice President of Finance, and Doug Atkinson, Senior Vice President of Global Sales, will participate in the Benchmark 14th Annual Discov</description>
</item>
<item>
<title>CapsoVision Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/capsovision-inc-common-stock/news/capsovision-reports-third-quarter-2025-210500481</link>
<guid isPermaLink="true">https://6ix.com/company/capsovision-inc-common-stock/news/capsovision-reports-third-quarter-2025-210500481</guid>
<pubDate>Thu, 13 Nov 2025 21:05:00 GMT</pubDate>
<description>SARATOGA, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for its third quarter ended September 30, 2025. Recent Highlights Third quarter 2025 revenue was $3.5 million, a 19% increase over the third quarter of 2024.New accounts grew 31% in the third quarter of 2025 over the comparable quarter in 2024.CapsoCam Plus® used b</description>
</item>
<item>
<title>CapsoVision Submits Breakthrough Device Designation Application to FDA for Pancreatic Cancer Screening Capsule</title>
<link>https://6ix.com/company/capsovision-inc-common-stock/news/capsovision-submits-breakthrough-device-designation-210500511</link>
<guid isPermaLink="true">https://6ix.com/company/capsovision-inc-common-stock/news/capsovision-submits-breakthrough-device-designation-210500511</guid>
<pubDate>Mon, 10 Nov 2025 21:05:00 GMT</pubDate>
<description>Non-invasive capsule endoscopy system aims to enable earlier detection of pancreatic ductal adenocarcinoma - among the most fatal cancers worldwideSARATOGA, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) on November 6, 2025 requesting Breakthrough Device</description>
</item>
<item>
<title>CapsoVision Appoints David Garcia as Senior Vice President of Finance</title>
<link>https://6ix.com/company/capsovision-inc-common-stock/news/capsovision-appoints-david-garcia-senior-130000130</link>
<guid isPermaLink="true">https://6ix.com/company/capsovision-inc-common-stock/news/capsovision-appoints-david-garcia-senior-130000130</guid>
<pubDate>Mon, 03 Nov 2025 13:00:00 GMT</pubDate>
<description>Seasoned finance executive brings public company, capital markets and transaction experience to support next phase of growthSARATOGA, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced the appointment of David Garcia as Senior Vice President of Finance, effective November 3, 2025. Mr. Garcia brings more than 20 years of financial leadership</description>
</item>
<item>
<title>CapsoVision to Release Third Quarter 2025 Financial Results on Thursday, November 13, 2025</title>
<link>https://6ix.com/company/capsovision-inc-common-stock/news/capsovision-release-third-quarter-2025-200500397</link>
<guid isPermaLink="true">https://6ix.com/company/capsovision-inc-common-stock/news/capsovision-release-third-quarter-2025-200500397</guid>
<pubDate>Thu, 30 Oct 2025 20:05:00 GMT</pubDate>
<description>Conference Call Scheduled for Thursday, November 13, 2025 at 4:30 pm ETSARATOGA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that the company will release third quarter 2025 financial results on Thursday, November 13, 2025, after the close of market. CapsoVision will host a corresponding conference call and a live webcast at 1:30 pm P</description>
</item>
<item>
<title>CapsoVision to Participate in the 4th Annual ROTH Healthcare Opportunities Conference</title>
<link>https://6ix.com/company/capsovision-inc-common-stock/news/capsovision-participate-4th-annual-roth-200500883</link>
<guid isPermaLink="true">https://6ix.com/company/capsovision-inc-common-stock/news/capsovision-participate-4th-annual-roth-200500883</guid>
<pubDate>Thu, 25 Sep 2025 20:05:00 GMT</pubDate>
<description>SARATOGA, Calif., Sept. 25, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that Johnny Wang, President and Chief Executive Officer, and Doug Atkinson, Head of Global Sales, will participate in the 4th Annual ROTH Healthcare Opportunities Conference, taking place on Thursday, October 9, 2025, in New York, NY. If you are interested in arranging a one-on-on</description>
</item>
<item>
<title>CapsoVision Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/capsovision-inc-common-stock/news/capsovision-reports-second-quarter-2025-200500216</link>
<guid isPermaLink="true">https://6ix.com/company/capsovision-inc-common-stock/news/capsovision-reports-second-quarter-2025-200500216</guid>
<pubDate>Thu, 14 Aug 2025 20:05:00 GMT</pubDate>
<description>SARATOGA, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for its second quarter ended June 30, 2025. Recent Highlights Second quarter 2025 revenue was $3.3 million, a 17% increase over the second quarter of 2024.New accounts grew 75% in the second quarter of 2025 over the comparable quarter in 2024.CapsoCam Plus® used by</description>
</item>
<item>
<title>CapsoVision to Release Second Quarter 2025 Financial Results on Thursday, August 14, 2025</title>
<link>https://6ix.com/company/capsovision-inc-common-stock/news/capsovision-release-second-quarter-2025-200500781</link>
<guid isPermaLink="true">https://6ix.com/company/capsovision-inc-common-stock/news/capsovision-release-second-quarter-2025-200500781</guid>
<pubDate>Thu, 31 Jul 2025 20:05:00 GMT</pubDate>
<description>- Conference Call Scheduled for Thursday, August 14, 2025 at 4:30 pm ET - SARATOGA, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in its capsule endoscopy solutions, today announced that the company will release second quarter 2025 financial results on Thursday, August 14, 2025, after the close of market. CapsoVision will host</description>
</item>
<item>
<title>CapsoVision Announces Closing of Initial Public Offering</title>
<link>https://6ix.com/company/capsovision-inc-common-stock/news/capsovision-announces-closing-initial-public-155000142</link>
<guid isPermaLink="true">https://6ix.com/company/capsovision-inc-common-stock/news/capsovision-announces-closing-initial-public-155000142</guid>
<pubDate>Thu, 03 Jul 2025 15:50:00 GMT</pubDate>
<description>SARATOGA, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in its capsule endoscopy solutions, today announced the closing of its initial public offering of 5,500,000 shares of common stock at a public offering price of $5.00 per share. The shares began trading on the Nasdaq Capital Market on July 2, 2025 under the ticker symbol “</description>
</item>
<item>
<title>CapsoVision Announces Pricing of Initial Public Offering</title>
<link>https://6ix.com/company/capsovision-inc-common-stock/news/capsovision-announces-pricing-initial-public-010800323</link>
<guid isPermaLink="true">https://6ix.com/company/capsovision-inc-common-stock/news/capsovision-announces-pricing-initial-public-010800323</guid>
<pubDate>Wed, 02 Jul 2025 01:08:00 GMT</pubDate>
<description>SARATOGA, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in its capsule endoscopy solutions, today announced the pricing of its initial public offering of 5,500,000 shares of common stock at a public offering price of $5.00 per share. The shares are expected to begin trading on the Nasdaq Capital Market on July 2, 2025 under the</description>
</item>
</channel>
</rss>